Molecular engineering of a theranostic molecule that detects Aβ plaques, inhibits Iowa and Dutch mutation Aβ self-aggregation and promotes lysosomal biogenesis for Alzheimer's disease-Reference-Cited by-同舟云学术

Molecular engineering of a theranostic molecule that detects Aβ plaques, inhibits Iowa and Dutch mutation Aβ self-aggregation and promotes lysosomal biogenesis for Alzheimer's disease

Published:2024 Issue:31 Volume:12 Page:7543-7556
ISSN:2050-750X
Container-title:Journal of Materials Chemistry B
language:en
Short-container-title:J. Mater. Chem. B

Author:

Iyaswamy Ashok¹²^ORCID,Wang Xueli³,Zhang Hailong³,Vasudevan Karthick⁴,Wankhar Dapkupar⁵,Lu Kejia¹,Krishnamoorthi Senthilkumar¹,Guan Xin-Jie¹,Su Cheng-Fu¹,Liu Jia¹,Kan Yuxuan¹,Jaganathan Ravindran⁶,Deng Zhiqiang¹,Li Hung-Wing⁷^ORCID,Wong Man Shing³^ORCID,Li Min¹

Affiliation:

1. Mr. & Mrs Ko Chi-Ming Centre for Parkinson's Disease Research, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, China

2. Department of Biochemistry, Karpagam Academy of Higher Education, Coimbatore, India

3. Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, China

4. Manipal Academy of Higher Education (MAHE), Manipal, 576104, India

5. Faculty of Paramedical Sciences, Assam down town University, Guwahati, Assam 781026, India

6. Preclinical Department, Faculty of Medicine, Royal College of Medicine Perak, Universiti Kuala Lumpur, Perak, Malaysia

7. Department of Chemistry, Chinese University of Hong Kong, Shatin, Hong Kong SAR, China

Abstract

Aβ specific theranostic small molecule, F-SLCOOH inhibits Aβ self-aggregation and promotes lysosomal biogenesis in Alzheimer’s disease models.

Funder

Hong Kong Baptist University

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/TB/D4TB00479E

Reference48 articles.

1. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data

2. Recent trends of natural based therapeutics for mitochondria targeting in Alzheimer’s disease

3. Is Alzheimer’s Disease Risk Modifiable?

4. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019

5. Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease